For Immediate Release

Organization Profile: 

Tim Shenk
Press Officer
Direct: 212-763-5764

Victory for Access to Medicines as Patent Rejected in India

GENEVA/NEW DELHI - The international medical humanitarian organization Doctors Without
Borders/Médecins Sans Frontières (MSF) welcomed the May 5 decision by
the Indian Patent Office to reject a product patent it had previously
granted to pharmaceutical company Roche for the drug valganciclovir. 

Valganciclovir is primarily used as treatment and prevention of an
infection caused by cytomegalovirus
in organ transplant patients, a highly lucrative market that
Roche has sought to protect by patenting the medicine. But CMV also
affects people living with HIV, and if left untreated, can cause
blindness and death. 

"Roche was attempting to patent a new form of a drug that was really
invented in the 1980s," said Leena Menghaney, project manager of the MSF
Campaign for Access to Essential Medicines
in India. "This decision
shows that Section 3(d) of India's Patents Act, which prevents
companies from filing unjustified patents, is working. Equally
importantly, the Patent Office also found separately that the patent
claims were obvious and therefore not patentable."

Through this decision, the Indian Patent Office has also confirmed the
right of patients groups to oppose a patent after it has been granted, a
matter on which Roche claimed there was ambiguity.  This follows a
similar recognition in 2002 in Thailand of patients as ‘persons
interested' in the outcome of a patent application.


Never Miss a Beat.

Get our best delivered to your inbox.

"For people living with HIV/AIDS in developing countries, accessing
valganciclovir at Roche prices was difficult," said Loon Gangte of the
Delhi Network of Positive People (DNP+), one of the patient groups that
filed an opposition to the patent. "The decision will provide much
needed relief as it secures the way for generic competition, which is
the most effective and sustainable way of bringing drug prices down."

To date, the price of valganciclovir is prohibitively expensive.  Roche
markets the drugs for up to US$8,500 for a four-month treatment course
in high-income countries. In India, the Roche price for a standard
protocol is approximately $5,950.  In December 2006, MSF approached
Roche for a discount, but even the ‘discounted' price was so high that
some MSF AIDS projects opted out of providing this treatment for CMV.

MSF will continue to follow this issue closely should Roche decide to


This is the world we live in. This is the world we cover.

Because of people like you, another world is possible. There are many battles to be won, but we will battle them together—all of us. Common Dreams is not your normal news site. We don't survive on clicks. We don't want advertising dollars. We want the world to be a better place. But we can't do it alone. It doesn't work that way. We need you. If you can help today—because every gift of every size matters—please do. Without Your Support We Simply Don't Exist.

Please select a donation method:

Doctors Without Borders/Médecins Sans Frontières (MSF) is an international medical humanitarian organization created by doctors and journalists in France in 1971. MSF's work is based on the humanitarian principles of medical ethics and impartiality. The organization is committed to bringing quality medical care to people caught in crisis regardless of race, religion, or political affiliation.
MSF operates independently of any political, military, or religious agendas.

Share This Article

More in: